Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997823 | 1.00 | TP53 (0.46) | TP53TAAR1CHRNB2CHRNA4HTR1A | |
| SCHEMBL15566598 | 0.91 | PTGDR2 (0.49) | TP53CHRNB2CHRNA4HTR1AADRA1B | |
| SCHEMBL126782 | 0.89 | PTGDR2 (0.50) | TP53CHRNB2CHRNA4HTR1AADRA1B | |
| SCHEMBL3781719 | 0.83 | CHRNB2 (0.61) | TAAR1CHRNB2CHRNA4TSHRPTGDR | |
| SCHEMBL433540 | 0.81 | GAA (0.52) | TP53TAAR1CHRNB2CHRNA4TSHR | |
| SCHEMBL3783984 | 0.79 | SLC6A2 (0.42) | TP53HTR1ACYP3A4CHRM4OPRL1 | |
| SCHEMBL31075301 | 0.79 | SLC9A1 (0.43) | TP53CHRNB2CHRNA4HTR1AADRA1B | |
| SCHEMBL25240757 | 0.78 | HTR3A (0.58) | CHRNB2CHRNA4HTR1A | |
| SCHEMBL30464830 | 0.78 | HTR3A (0.58) | CHRNB2CHRNA4HTR1A | |
| SCHEMBL3406995 | 0.77 | CYP3A4 (0.45) | TAAR1CHRNB2CHRNA4HTR1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442990-B2 | Mesogenic compounds, liquid crystal media and components for high frequency technology | MERCK PATENT GMBH (DE) | 2019-10-15 | — | — | US | disclosed |
| US-10442990-B2 | Mesogenic compounds, liquid crystal media and components for high frequency technology | MERCK PATENT GMBH (DE) | 2019-10-15 | — | — | US | disclosed |
| US-9765259-B2 | Mesogenic compounds, liquid-crystalline media and components for high-frequency technology | MERCK PATENT GMBH (DE) | 2017-09-19 | — | — | US | disclosed |
| US-9765259-B2 | Mesogenic compounds, liquid-crystalline media and components for high-frequency technology | MERCK PATENT GMBH (DE) | 2017-09-19 | — | — | US | disclosed |
| US-9765259-B2 | Mesogenic compounds, liquid-crystalline media and components for high-frequency technology | MERCK PATENT GMBH (DE) | 2017-09-19 | — | — | US | disclosed |
| US-9752077-B2 | Liquid-crystalline media, components for high-frequency technology, and mesogenic compounds | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9752077-B2 | Liquid-crystalline media, components for high-frequency technology, and mesogenic compounds | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9752077-B2 | Liquid-crystalline media, components for high-frequency technology, and mesogenic compounds | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9523037-B2 | Liquid-crystalline media, components for high-frequency technology, and mesogenic compounds | MERCK PATENT GMBH (DE) | 2016-12-20 | — | — | US | disclosed |
| US-9523037-B2 | Liquid-crystalline media, components for high-frequency technology, and mesogenic compounds | MERCK PATENT GMBH (DE) | 2016-12-20 | — | — | US | disclosed |
| WO-2012126563-A1 | MESOGENIC COMPOUNDS, LIQUID CRYSTAL MEDIA AND COMPONENTS FOR HIGH FREQUENCY TECHNOLOGY | MERCK PATENT GMBH (DE) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012126576-A1 | MESOGEN COMPOUNDS, LIQUID CRYSTALLINE MEDIA AND COMPONENTS FOR HIGH FREQUENCY TECHNOLOGY | MERCK PATENT GMBH (DE) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012126576-A1 | MESOGEN COMPOUNDS, LIQUID CRYSTALLINE MEDIA AND COMPONENTS FOR HIGH FREQUENCY TECHNOLOGY | MERCK PATENT GMBH (DE) | 2012-09-27 | — | — | WO | disclosed |
| US-20120205583-A1 | COMPOUNDS FOR A LIQUID CRYSTAL MEDIUM AND HIGH-FREQUENCY COMPONENTS CONTAINING SAID LIQUID CRYSTAL MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120205583-A1 | COMPOUNDS FOR A LIQUID CRYSTAL MEDIUM AND HIGH-FREQUENCY COMPONENTS CONTAINING SAID LIQUID CRYSTAL MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120205583-A1 | COMPOUNDS FOR A LIQUID CRYSTAL MEDIUM AND HIGH-FREQUENCY COMPONENTS CONTAINING SAID LIQUID CRYSTAL MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-08-16 | — | — | US | disclosed |
| WO-2012097853-A1 | LIQUID CRYSTALLINE MEDIA, COMPONENTS FOR HIGH FREQUENCY TECHNOLOGY AND MESOGENIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | WO | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| WO-2011035849-A1 | COMPOUNDS FOR A LIQUID CRYSTAL MEDIUM AND HIGH-FREQUENCY COMPONENTS CONTAINING SAID LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2011-03-31 | — | — | WO | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120205583-A1 | COMPOUNDS FOR A LIQUID CRYSTAL MEDIUM AND HIGH-FREQUENCY COMPONENTS CONTAINING SAID LIQUID CRYSTAL MEDIUM | CHRM1, CXCR1, CCNL2 | TP53 2819/4885TAAR1 180/4885CHRNB2 2187/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | TP53 1977/4885TAAR1 1938/4885CHRNB2 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.